Blood-based test can predict risk of developing symptoms of Alzheimer's up to a decade early
A new international study published in JAMA indicates that a blood test for the p-tau217 biomarker can predict the risk of cognitive impairment in healthy individuals up to a decade in advance. While promising, experts caution that the test is not currently recommended for asymptomatic individuals due to the lack of available disease-modifying treatments.
Why it matters
Early detection of Alzheimer's risk is a major medical milestone, though it raises ethical and practical questions about how to manage patient expectations without effective cures.
edited by Sadie Harley , reviewed by Andrew Zinin
The report relies on peer-reviewed medical research and includes expert commentary, maintaining a neutral, evidence-based tone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in